Amicus Therapeutics Inc. (NASDAQ:FOLD)’s share price fell 2.9% during trading on Tuesday . The company traded as low as $5.90 and last traded at $5.94, with a volume of 609,378 shares. The stock had previously closed at $6.12.

A number of brokerages have recently commented on FOLD. Robert W. Baird began coverage on shares of Amicus Therapeutics in a report on Wednesday, April 13th. They set a “neutral” rating and a $9.00 price target on the stock. Goldman Sachs Group Inc. began coverage on shares of Amicus Therapeutics in a report on Wednesday, March 30th. They issued a “neutral” rating and a $10.00 target price on the stock. Chardan Capital boosted their target price on shares of Amicus Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, April 12th. Leerink Swann restated an “outperform” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Wednesday, June 1st. Finally, Bank of America Corp. began coverage on shares of Amicus Therapeutics in a report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 target price on the stock. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $12.88.

The company’s market capitalization is $749.59 million. The firm’s 50 day moving average is $6.10 and its 200-day moving average is $6.94.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.01. On average, analysts predict that Amicus Therapeutics Inc. will post ($1.35) EPS for the current year.

In related news, General Counsel Ellen Rosenberg bought 15,000 shares of the business’s stock in a transaction on Thursday, June 2nd. The stock was acquired at an average cost of $7.67 per share, with a total value of $115,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Several hedge funds recently modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Amicus Therapeutics by 3.3% in the fourth quarter. Jennison Associates LLC now owns 4,123,955 shares of the biopharmaceutical company’s stock worth $40,002,000 after buying an additional 133,138 shares during the period. ProShare Advisors LLC increased its stake in shares of Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 15,789 shares during the period. California Public Employees Retirement System increased its stake in shares of Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock worth $3,163,000 after buying an additional 11,600 shares during the period. TD Asset Management Inc. increased its stake in shares of Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock worth $1,733,000 after buying an additional 2,600 shares during the period. Finally, Swiss National Bank increased its stake in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 5,100 shares during the period.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.